The Worldwide Proton Therapy Industry is Projected to Reach $1.5 Billion by 2031
04 nov. 2022 06h33 HE | Research and Markets
Dublin, Nov. 04, 2022 (GLOBE NEWSWIRE) -- The "Proton Therapy Market By Indication, By Product Type, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added...
Japan Proton Therapy Market to Reach $8.6 Billion by 2027 at a 5.9% CAGR
13 oct. 2022 05h08 HE | Research and Markets
Dublin, Oct. 13, 2022 (GLOBE NEWSWIRE) -- The "Japan Proton Therapy Market, Share, Forecast 2022-2027, Industry Trends, Growth, Size, Impact of COVID-19, Company Analysis" report has been added to ...
Radiopharmaceuticals Global Market Report 2022: Industry Focus Gears up for Innovative Radiopharmaceuticals with Therapeutic Benefits
23 août 2022 06h13 HE | Research and Markets
Dublin, Aug. 23, 2022 (GLOBE NEWSWIRE) -- The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to's offering. Global...
Global Radiotherapy Market Report 2022: Growing Use of Particle Therapy for Cancer Treatment & Awareness Initiatives on the Benefits of Radiotherapy Driving Growth
18 août 2022 05h53 HE | Research and Markets
Dublin, Aug. 18, 2022 (GLOBE NEWSWIRE) -- The "Radiotherapy Market by Type (Product, Service), Technology (LINAC, Stereotactic LINAC, Particle Therapy, Cobalt-60 Teletherapy), Procedure (IMRT, IGRT,...
ITM Acquires a New Platform for the Development of Next-Generation Theranostics
18 août 2022 05h18 HE | ITM Isotope Technologies Munich SE
• Technology platform for PET tracers strengthens ITM’s radiodiagnostic portfolio • Additional assets potentially expand ITM’s pipeline of novel targeted radionuclide therapeutics Garching /...
ITM Appoints Dr. Sebastian Marx as Chief Business Officer and Member of Executive Board
22 juil. 2022 05h00 HE | ITM Isotope Technologies Munich SE
Garching / Munich, July 22, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Sebastian Marx to its Executive Board...
ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177
21 juil. 2022 05h21 HE | ITM Isotope Technologies Munich SE
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA Complex for GD2-positive...
AMR Logo.png
Radiotherapy Market Is Expected to Reach $11.9 Billion by 2031, Claims AMR
07 juil. 2022 07h50 HE | Allied Market Research
Portland, OR, July 07, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global radiotherapy market generated $6.5 billion in 2021, and is projected to reach...
Global Radiation Therapy Market Report 2022: Surging Incidence of Cancer Cases & Rising Healthcare Expenditure to Drive Growth
06 juil. 2022 05h03 HE | Research and Markets
Dublin, July 06, 2022 (GLOBE NEWSWIRE) -- The "Global Radiation Therapy Market with Focus on LINAC: Insights & Forecast with Potential Impact of COVID-19 (2022-2026)" report has been added to...
ITM: New Isotope Production System at Bruce Power Successfully Produces First Medical Isotope
21 juin 2022 11h45 HE | ITM Isotope Technologies Munich SE
First-of-a-kind Isotope Production System continues to progress towards commercial, industrial-scale production of medical isotopes for cancer therapeutics ONTARIO, CANADA, and MUNICH, GERMANY – June...